Current Report Filing (8-k)
2021年9月30日 - 9:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest reported): September 30, 2021
Novo
Integrated Sciences, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
001-40089
|
|
59-3691650
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
Number)
|
11120
NE 2nd Street, Suite 100, Bellevue, WA 98004
(Address
of principal executive offices)
(206)
617-9797
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2.)
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol(s)
|
|
Name
of Each Exchange on which Registered
|
Common
Stock, $0.001 par value
|
|
NVOS
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01. Regulation FD Disclosure.
Beginning
on September 30, 2021, management of Novo Integrated Sciences, Inc. (the “Company”) will deliver the investor presentation
attached hereto as Exhibit 99.1 and incorporated herein by reference.
The
information included in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended
(the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
The information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current
Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.
Forward-Looking
Statements
This
Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E
of the Exchange Act. All statements other than statements of historical facts included in this report are forward-looking statements.
In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,”
“anticipate,” “plan,” “potential,” “continue,” “will,” “would”
or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause
actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties
are discussed in the registrant’s filings with the Securities and Exchange Commission (the “SEC”). Investors should
not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which
are, in some cases, beyond the registrant’s control which could, and likely will, materially affect actual results, levels of activity,
performance or achievements. Any forward-looking statement reflects the registrant’s current views with respect to future events
and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy
and liquidity. The registrant assumes no obligation to publicly update or revise these forward-looking statements for any reason, or
to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new
information becomes available in the future.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Novo
Integrated Sciences, Inc.
|
|
|
|
Dated:
September 30, 2021
|
By:
|
/s/
Robert Mattacchione
|
|
|
Robert
Mattacchione
|
|
|
Chief
Executive Officer
|
Novo Integrated Sciences (NASDAQ:NVOS)
過去 株価チャート
から 6 2024 まで 7 2024
Novo Integrated Sciences (NASDAQ:NVOS)
過去 株価チャート
から 7 2023 まで 7 2024